John Temperato is CEO at INNOVATE BIOPHARMACEUTICALS, INC. (NMTR). They have made 10 open-market trades across 1 company since 2020, most recently 2023-03-27.
CIK 0001722407
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
10 open-market purchases totalling $616K since 2020, never a sale. Across 10 scored buys the stock is up 11.0% at ninety days, and 7.7 points ahead of the S&P over the same stretch.
10 scored purchases · one row per filing · discretionary only
| Ticker | Shares | Value |
|---|---|---|
| NMTR | 140,192 | $10K |
Shares reported on the most recent Form 4, priced at the 2023-03-29 close.
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 30% | 60% | 40% |
| Avg Move | -3.6% | +2.7% | +11.0% |
| Alpha | -4.7% | +2.2% | +7.7% |
| Scored | 10 | 10 | 10 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| NMTR | BUY | 2022-07-06 | 2022-07-08 | $0.23 | $29K | +4.7% | +8.3% | -7.9% |
| NMTR | BUY | 2022-05-18 | 2022-05-19 | $0.45 | $23K | -3.3% | -37.0% | -34.1% |
| NMTR | BUY | 2022-03-03 | 2022-03-04 | $0.56 | $112K | -0.3% | +7.5% | -17.6% |
| NMTR | BUY | 2021-11-18 | 2021-11-19 | $1.05 | $53K | -12.3% | -11.4% | -38.2% |
| NMTR | BUY | 2021-08-18 | 2021-08-19 | $1.05 | $26K | +18.2% | +11.8% | -4.5% |
| NMTR | BUY | 2021-04-05 | 2021-04-06 | $1.00 | $100K | -12.0% | -6.4% | -14.4% |
| NMTR | BUY | 2020-12-15 | 2020-12-17 | $0.65 | $200K | +4.3% | +49.1% | +98.4% |
| NMTR | BUY | 2020-08-21 | 2020-08-24 | $0.69 | $48K | -5.8% | +18.5% | +80.2% |
| NMTR | BUY | 2020-08-17 | 2020-08-17 | $0.57 | $20K | -18.4% | +1.4% | +27.4% |
| NMTR | BUY | 2020-06-15 | 2020-06-15 | $0.60 | $6K | -10.9% | -14.9% | +20.7% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.